Bayesian value-of-information analysis: An application to a policy model of Alzheimer's disease

International Journal of Technology Assessment in Health Care

Volumn 17, Issue 1, 2001, Pages 38-55

  Claxton, Karl ^a   Neumann, Peter J ^b   Araki, Sally ^b   Weinstein, Milton C ^b  

^a UNIVERSITY OF YORK   (United Kingdom)

^b HARVARD CENTER FOR RISK ANALYSIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL;

ALZHEIMER DISEASE; BAYES THEOREM; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; HUMAN; POLICY; PROBABILITY; REVIEW;

ALZHEIMER DISEASE; BAYES THEOREM; COST-BENEFIT ANALYSIS; DECISION THEORY; DISEASE PROGRESSION; HUMANS; INDANS; INFORMATION STORAGE AND RETRIEVAL; NOOTROPIC AGENTS; PIPERIDINES; POLICY MAKING; TECHNOLOGY ASSESSMENT, BIOMEDICAL; TREATMENT OUTCOME; UNITED STATES; VALUE OF LIFE;

EID: 0035027841     PISSN: 02664623     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0266462301104058     Document Type: Review

References (45)

1. Bayesian methods in health related research
2. Bayesian approach to stochastic cost-effectiveness analysis
3. Probabilistic analysis of decision trees using Monte Carlo simulation
4. Bayesian approaches to the value of information: Implications for the regulation of new pharmaceuticals
5. The irrelevance of inference: A decision making approach to the stochastic evaluation of health care technologies
6. An economic approach to clinical trial design and research priority setting
7. A utility based approach to decision making with multiple disease state process
8. Large scale randomised evidence: Trials and overviews
9. Probabilistic sensitivity analysis using Monte Carlo simulation
10. Economic analysis alongside clinical trials: Revisiting the methodological issues
11. Policy statement on advertising substantiation
12. Sensitivity analysis and the expected value of perfect information
13. Economic foundations of cost-effectiveness analysis
14. Information value theory
15. Alzheimer's disease care: Costs and potential savings
16. Discussion of the paper by Spiegelhalter, Freedman, and Parmar
17. The marginal cost-effectiveness of medical technology: A panel instrumental-variables approach
18. The clinical dementia rating (CDR): Current version and scoring rules
19. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD), part 1: Clinical and neuropsychological assessment of Alzheimer's disease
20. The FDA's regulation of health economic information: Issues and options for Section 114 of FDAMA
21. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease
22. Health utilities in Alzheimer's disease: A cross sectional study of patients and caregivers
23. Willingness to pay and the distribution of risk and wealth
24. The economic burden of Alzheimer's disease care
25. A 24-week, double blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
26. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: An interim analysis of the results of a US multicentre open label extension study
27. The pure theory of public good expenditure
28. Markov models in medical decision making: A practical guide
29. Bayesian approaches to randomised trials
30. Estimating C/E ratios under second order uncertainty: The mean ratio versus the ratio of the means
31. Monte Carlo techniques for quantitative uncertainty analysis in public health risk assessments
32. The value of improved national exposure information for perchloroethylene (perc): A case study for dry cleaners
33. Going beyond the single number: Using probabilistic risk assessment to improve risk management
34. Multi-attribute preference functions for a comprehensive health status classification systems: Health Utilities Index Mark 2